An immunolayer chromatography technology platform utilizing fluorescence detection for rapid diagnostic testing. Provides high sensitivity across multiple analyte categories including thyroid markers.
Manufactured by
China
Xenta Biomedical Science Co., Ltd, founded in December 2021 and headquartered in Guangzhou Development District, is a national high-tech enterprise focused on the R&D, registration, and commercialization of in vitro diagnostic (IVD) reagents and devices. With fully paid-up capital of RMB 10 million, the company is led by a team of returnee PhDs with strong international research and industry experience. It is dedicated to developing innovative POCT technology platforms under the philosophy of "Faster, Better, and More Accessible". The company drives innovation through R&D centers in Guangzhou, Xiamen, and overseas. Using its proprietary dry light-excited chemiluminescence POCT platform, it has developed leading product series and managed major national research projects. The company has published over 20 SCI papers, holds 70 patents, has obtained more than 60 EU CE certifications, and 12 FDA approvals in the United States. Currently, several product lines are actively striving for NMPA certification. Its pipeline covers key areas including cardiovascular, inflammation, oncology, hormone, and infectious diseases, demonstrating end-to-end capabilities from R&D to global commercialization. The core team comprises graduates from top universities such as Texas A&M University, Xiamen University, Sanford-Burnham Medical Research Institute, and Sun Yat-sen University, possessing multidisciplinary expertise in biomedicine, engineering, and law. The co-founders have extensive experience from leading IVD companies, having previously guided teams to achieve annual revenues exceeding several hundred million yuan and secure over 200 product certifications worldwide. Since its establishment, Xenta Biomedical Science Co., Ltd has raised tens of millions in funding and obtained ISO 13485 certification, supporting its global expansion.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Guangzhou Wondfo Biotech Co., Ltd.
China · 1 relevant product
ReLIA Bioengineering(Jiangsu), Inc
China · 1 relevant product
Beijing Zhongjian Antai Diagnostic Co., Ltd.
China · 1 relevant product
Shenzhen YHLO Biotech Co., Ltd.
China · 3 relevant products
Vitrosens Biyoteknoloji Anonim Sirketi
Türkiye · 2 relevant products
B&C Biological
China · 1 relevant product
S&T BioMed CO., LTD.
Taiwan · 1 relevant product
Jiangsu Sunlant Bioengineering Co., Ltd.
China · 1 relevant product
SA Scientific Ltd.
United States · 1 relevant product
Shenzhen Microprofit Biotech Co., Ltd
China · 3 relevant products
15 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 33 closest product alternatives
Guangzhou Wondfo Biotech Co., Ltd. · China
Immunofluorescence-based diagnostic platform for detection and identification of specific antigens or antibodies in clinical samples. Provides fluorescence-based results for rapid point-of-care and laboratory testing.
ReLIA Bioengineering(Jiangsu), Inc · China
A diagnostic platform for point-of-care testing (POCT) that uses immunofluorescence technology for rapid and accurate detection. The platform features precise temperature control, multiple connectivity options, and automatic sample identification to enable quick diagnostic testing.
Beijing Zhongjian Antai Diagnostic Co., Ltd. · China
Fluorescence quantitative immunoassay platform for in vitro diagnostic testing of infectious diseases, respiratory pathogens, and gastrointestinal markers. The system enables quantitative analysis using fluorescence immunoassay technology with Class II medical device certification across multiple regulatory markets. Supports high-throughput diagnostic workflows in clinical laboratories and reference testing facilities.
Shenzhen YHLO Biotech Co., Ltd. · China
An indirect immunofluorescence technology platform for serological testing and antibody detection. The system is utilized for diagnosis of autoimmune and infectious diseases through fluorescence-based immunoassay methodology.
Shenzhen YHLO Biotech Co., Ltd. · China
A comprehensive technology platform utilizing chemiluminescence immunoassay methodology for in vitro diagnostic testing. The platform enables sensitive and specific detection of various clinical markers including reproductive, autoimmune, infectious disease, and metabolic parameters.
Vitrosens Biyoteknoloji Anonim Sirketi · Türkiye
Immunofluorescence-based diagnostic platform for thyroid marker testing with accurate and reliable clinical results.
Vitrosens Biyoteknoloji Anonim Sirketi · Türkiye
Immunofluorescence-based diagnostic platform for infectious disease detection providing accurate and fast results.
B&C Biological · China
A fluorescence-based immunoassay platform from the POCT series designed for rapid diagnostic testing. The SF-100 platform enables high-sensitivity and high-precision immunofluorescence detection for various clinical analytes and sample types.
S&T BioMed CO., LTD. · Taiwan
Automated immunoassay system utilizing electrochemical detection methods for biomarker quantification. Suitable for high-throughput clinical laboratory applications.
Shenzhen YHLO Biotech Co., Ltd. · China
A rapid immunochromatographic testing platform utilizing colloidal gold technology for point-of-care and laboratory diagnostics. The system provides quick visual results for various clinical markers and infectious disease screening.
Jiangsu Sunlant Bioengineering Co., Ltd. · China
A microarray-based chemiluminescence immunoassay platform using hard-substrate glass slides as carriers with covalently bound monoclonal antibodies. The platform features integrated positive and negative quality control points, multi-parameter detection with up to 56 array points, and a sandwich immunoassay methodology. It combines high-sensitivity chemiluminescence detection with high-throughput biochip technology using an integrated photoelectric sensor to read all signal points simultaneously.
SA Scientific Ltd. · United States
High-sensitivity diagnostic test platform utilizing fluorescent-based lateral flow technology. Enables rapid automated detection with enhanced sensitivity compared to visual membrane-based tests.
21 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products